Calypso Medical Technologies, Inc.
RELATED CONTENT
October 29, 2010 – The first clinical study has been initiated to evaluate the use of the Calypso System for tracking lung cancer tumors during radiation delivery, including a new design of the company's implantable Beacon transponder. Calypso Medical Technologies Inc. has developed real-time localization technology used for the precise tracking of tumors.
October 29, 2010 
October 20, 2010 – The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a system designed to automate the response to organ motion during prostate cancer radiotherapy. The Calypso System, by Calypso Medical Technologies, could help decrease the side effects associated with prostate radiotherapy, such as bowel and bladder incontinence and sexual dysfunction.
October 20, 2010 
August 23, 2010 - Calypso Medical Technologies Inc., entered into a distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.
The Calypso System is a real-time localization technology used for the precise tracking of tumor targets.
August 23, 2010 June 16, 2010 -- Dynamic EdgeT Gating Technology, the latest innovation of the Calypso System from Calypso Medical Technologies Inc., allows therapists to set motion thresholds which disable radiation delivery if the targeted tissue moves outside the preset threshold. The technology will be demonstrated at the 52nd Annual Meeting of the American Association of Physicists in Medicine, July 18-21.
July 16, 2010 February 15, 2010 - New data released shows targeted radiotherapy, using real-time prostate tumor tracking during external beam radiation, enables the delivery of high doses of radiation, while reducing treatment-related side effects, including bowel urgency, rectal irritation and urinary irritation.
February 15, 2010 
November 2, 2009 - Calypso Medical Technologies, Inc. today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.
November 03, 2009 Prostate cancer is the second leading cause of cancer death for men after lung cancer. The American Cancer Society estimates that 29,412 men died from prostate cancer in 2008. However, most experts agree that prostate cancer is treatable and highly curable if the disease is detected early.
October 06, 2009 
Known as GPS for the Body technology, the Calypso System utilizes miniature implanted Beacon transponders to provide precise, continuous, real-time information about the location of the tumor target during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, has the potential to compromise treatment accuracy.
September 29, 2009 
July 29, 2009 – At the AAPM 51st Annual Meeting, Calypso Medical Technologies touted its strategic development agreement with Varian Medical Systems to jointly develop products integrating its Calypso System with Varian’s radiotherapy treatment technologies.
July 29, 2009 June 18, 2009 - Calypso Medical Technologies announced the publication of three new studies investigating the role of the Calypso 4D Localization System in guiding immediate adjustments to radiation delivery in response to tumor motion, a concept known as real-time adaptive radiation treatment.
June 19, 2009